CN114728066A - 与乙型肝炎的人中和抗体相关的组合物和方法 - Google Patents

与乙型肝炎的人中和抗体相关的组合物和方法 Download PDF

Info

Publication number
CN114728066A
CN114728066A CN202080078339.7A CN202080078339A CN114728066A CN 114728066 A CN114728066 A CN 114728066A CN 202080078339 A CN202080078339 A CN 202080078339A CN 114728066 A CN114728066 A CN 114728066A
Authority
CN
China
Prior art keywords
ser
gly
prt
tyr
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080078339.7A
Other languages
English (en)
Chinese (zh)
Inventor
王乔
米歇尔·努森茨威格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of CN114728066A publication Critical patent/CN114728066A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080078339.7A 2019-09-11 2020-09-11 与乙型肝炎的人中和抗体相关的组合物和方法 Pending CN114728066A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962898735P 2019-09-11 2019-09-11
US62/898,735 2019-09-11
US202062982276P 2020-02-27 2020-02-27
US62/982,276 2020-02-27
PCT/US2020/050509 WO2021050954A1 (en) 2019-09-11 2020-09-11 Compositions and methods related to human neutralizing antibodies to hepatitis b

Publications (1)

Publication Number Publication Date
CN114728066A true CN114728066A (zh) 2022-07-08

Family

ID=74866658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080078339.7A Pending CN114728066A (zh) 2019-09-11 2020-09-11 与乙型肝炎的人中和抗体相关的组合物和方法

Country Status (7)

Country Link
US (1) US20220315645A1 (https=)
EP (1) EP4021503A4 (https=)
JP (1) JP7629649B2 (https=)
KR (1) KR20220080102A (https=)
CN (1) CN114728066A (https=)
CA (1) CA3154556A1 (https=)
WO (1) WO2021050954A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87105411A (zh) * 1986-06-20 1988-08-24 斯克里普斯哈床学与研究基金会 B型肝炎病毒表面抗原前s区的t细胞和b细胞抗原决定基
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
CN105899658A (zh) * 2013-12-12 2016-08-24 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
KR20150070181A (ko) * 2012-09-27 2015-06-24 크루셀 홀란드 비.브이. B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87105411A (zh) * 1986-06-20 1988-08-24 斯克里普斯哈床学与研究基金会 B型肝炎病毒表面抗原前s区的t细胞和b细胞抗原决定基
CN105899658A (zh) * 2013-12-12 2016-08-24 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RACHEL EREN等: "Preclinical Evaluation of Two Human Anti–Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV-Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees", HEPATOLOGY, vol. 32, no. 3, 31 December 2000 (2000-12-31), pages 588 - 596, XP029576855, DOI: 10.1053/jhep.2000.9632 *
YONG-WON SHIN等: "Human monoclonal antibody against Hepatitis B virus surface antigen (HBsAg)", ANTIVIRAL RESEARCH, 31 December 2007 (2007-12-31), pages 113 - 120 *

Also Published As

Publication number Publication date
EP4021503A4 (en) 2024-02-14
CA3154556A1 (en) 2021-03-18
JP2022547551A (ja) 2022-11-14
WO2021050954A1 (en) 2021-03-18
EP4021503A1 (en) 2022-07-06
JP7629649B2 (ja) 2025-02-14
KR20220080102A (ko) 2022-06-14
US20220315645A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
Wang et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations
Hehle et al. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers
JP6483337B2 (ja) デングウイルス血清型１のｅタンパク質に対して特異性を有するヒトモノクローナル抗体およびその使用
AU2015206002B2 (en) Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
CN109641952A (zh) 抗兹卡病毒抗体和使用方法
CN114539391A (zh) 中和乙型肝炎病毒的抗体和其用途
CN102264393B (zh) 作为治疗和预防hcv感染药物的抗hcv单克隆抗体
CN102584947B (zh) 针对丙型肝炎病毒e1e2 复合体的抗体、hcv 颗粒的组合物和药物组合物
CN1545551B (zh) 针对丙型肝炎病毒e2糖蛋白的人单克隆抗体
CN114728066A (zh) 与乙型肝炎的人中和抗体相关的组合物和方法
KR20220012297A (ko) 항-b형 간염 바이러스 항체 및 이의 용도
Kim et al. Construction of a humanized antibody to hepatitis B surface antigen by specificity-determining residues (SDR)-grafting and de-immunization
US20240327500A1 (en) Anti-hbv antibodies and uses thereof
WO2002045743A2 (en) Hcv vaccines
Wang et al. Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity
JPH02504284A (ja) 抗原、および、抗イディオタイプ抗体、または抗原に対する細胞受容体に特異的な抗体に共通のアミノ酸配列に由来する免疫原および生物学的活性ペプチド
Beretta et al. In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus
Huang et al. Development and structural characterization of a two-MAb cocktail for delayed treatment of enterovirus D68 infections
Irvine Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
CN117042797A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法
Chan et al. Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination